EOLSEvolus, Inc.
Price
+24%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, growing in the filings, the market undecided.
Charts
As reported to the SEC, without any scoring.
Evolus, Inc. (EOLS) reported revenue of $84M in Q2 2026 (quarter ended Jun 30, 2026), up 21% from the same quarter a year earlier. That came with a gross margin of 68% and net loss of $8.1M. For the full year FY2025, revenue was $297M (+12% year on year) and net income −$52M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook.Earnings release · press release
- Aug 4, 2026Symatese License Amendment - Addition of Australia, New Zealand and Canada On August 3, 2026, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”), and Symatese Aesthetics S.A.S. (“Symatese”) entered into an amendment (the “Amendment”) to the License, Supply and Distribution …Material agreement entered · Form 8-K
- Jul 8, 2026IBSA License Agreement - Profhilo ® On July 7, 2026, Evolus, Inc. (the “Company”) and IBSA Institut Biochimique SA (“IBSA”) entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which IBSA granted to the Company an exclusive right and license to develop, commercialize and distribute …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #35 of 41 by RyuScore